The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer


YILDIZ R., Benekli M., Buyukberber S., Kaya A. O. , Ozturk B., Yaman E., ...More

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.136, no.10, pp.1471-1476, 2010 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 136 Issue: 10
  • Publication Date: 2010
  • Doi Number: 10.1007/s00432-010-0803-1
  • Title of Journal : JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • Page Numbers: pp.1471-1476

Abstract

Bevacizumab-based chemotherapy has become the standard of care in metastatic colorectal cancer (MCRC). We aimed to measure the levels of serum soluble FAS, FASL, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), and its death receptors DR4 and DR5 in MCRC patients and to define prognostic significance of these parameters in response to bevacizumab in these patients.